Literature DB >> 32186065

Effect of Ningmitai capsule plus sertraline on patients with premature ejaculation and enlarged seminal vesicles: A randomized clinical trial.

Longping Peng1, Bing Yao1, Zhiwei Hong2, Jiaming Shen2, Xuechun Hu2, Yong Shao2, Jun Jing2, Jinchun Lu3.   

Abstract

OBJECTIVE: To investigate the effects of Ningmitai capsule combined with sertraline on patients with premature ejaculation (PE) and an increased anterior-posterior diameter (APD) of the seminal vesicles (SVs).
METHODS: Sixty men with acquired PE were enrolled and randomly divided into two groups. The combined group was treated with Ningmitai capsule and sertraline, while the control group was treated with sertraline alone. Main outcomes were measured using the premature ejaculation diagnostic tool (PEDT), APD of SVs, and Clinical Global Impression of Change questionnaire and compared before and after 3 months of treatment.
RESULTS: Comparing after treatment with before treatment outcomes within each group, the PEDT score was significantly reduced in the combined group (12.1 ¡À 2.5 vs 8.6 ¡À 3.2, P < 0.001, respectively) and control group (12.9 ¡À 2.6 vs 10.3 ¡À 1.6, P < 0.001, respectively). Furthermore, the PEDT score after treatment was significantly lower in the combined compared with control group (8.6 ¡À 3.2 vs 10.3 ¡À 1.6, P = 0.011, respectively). The APD of SVs in the combined group was significantly decreased after treatment [(10.8 ¡À 2.4) vs (12.9 ¡À 2.2) mm, P = 0.001], while the APD of SVs in the control group was equivalent before and after treatment. The treatment response rate was not significantly higher in the combined compared with control group.
CONCLUSION: These results indicated that the effect of Ningmitai capsule combined with sertraline was better than that of sertraline alone for the treatment of PE patients exhibiting an increased APD of SVs. The therapeutic effect found for the combined treatment may be due to antibacterial and anti-inflammatory activity reported for Ningmitai capsule, and may suggest that seminal vesiculitis is a potential pathophysiological factor in acquired PE.

Entities:  

Keywords:  Ningmitai capsule; Premature ejaculation; Randomized clinical trials; Seminal vesicles; Therapeutics

Year:  2018        PMID: 32186065

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  2 in total

1.  The Anti-Inflammatory and Antioxidative Effects of Ningmitai Capsule in the Experimental Autoimmune Prostatitis Rat Model.

Authors:  Haicheng Chen; Yun Xie; Cuncan Deng; Chi Zhang; Linyan Lv; Jiahui Yao; Xiangzhou Sun; Chunhua Deng; Guihua Liu
Journal:  Evid Based Complement Alternat Med       Date:  2020-05-28       Impact factor: 2.629

2.  Ningmitai capsule promotes calculi expulsion after RIRS for 10-20-mm upper urinary stones: a multicenter, prospective, randomized controlled trial.

Authors:  Ruofan Wang; Qingdong Qiao; Dengke Yang; Jianguo Zhang; Chaoyang Zhu; Jiantao Sun; Zhongling Dou; Xiaofu Wang; Huiming Zhang; Wenhao Wang; Fei Xiao; Hepeng Cheng; Wenwei Lv; Bo Zhou; Xiaofan Zhang; Wuxue Li; Xinghua Zhao; Bin Hao; Changbao Xu
Journal:  Urolithiasis       Date:  2022-01-25       Impact factor: 3.436

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.